MA41052A - Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii - Google Patents

Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii

Info

Publication number
MA41052A
MA41052A MA041052A MA41052A MA41052A MA 41052 A MA41052 A MA 41052A MA 041052 A MA041052 A MA 041052A MA 41052 A MA41052 A MA 41052A MA 41052 A MA41052 A MA 41052A
Authority
MA
Morocco
Prior art keywords
treatment
cardiovascular disease
actrii ligand
ligand traps
traps
Prior art date
Application number
MA041052A
Other languages
English (en)
Inventor
Nianhang Chen
Yifu Fang
Keith Hruska
William Smith
Original Assignee
Celgene Corp
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp, Univ Washington filed Critical Celgene Corp
Publication of MA41052A publication Critical patent/MA41052A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
MA041052A 2014-10-09 2015-10-07 Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii MA41052A (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462062021P 2014-10-09 2014-10-09
US201462078321P 2014-11-11 2014-11-11
US201562103515P 2015-01-14 2015-01-14
US201562167052P 2015-05-27 2015-05-27
US201562170015P 2015-06-02 2015-06-02

Publications (1)

Publication Number Publication Date
MA41052A true MA41052A (fr) 2017-08-15

Family

ID=55858162

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041052A MA41052A (fr) 2014-10-09 2015-10-07 Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii

Country Status (15)

Country Link
US (1) US11813308B2 (fr)
EP (1) EP3204118B8 (fr)
JP (2) JP2017533191A (fr)
KR (1) KR20170088836A (fr)
CN (1) CN107206255A (fr)
AU (2) AU2015339786B2 (fr)
CA (1) CA2964129A1 (fr)
ES (1) ES2978963T3 (fr)
HK (1) HK1244741A1 (fr)
IL (1) IL251649B (fr)
MA (1) MA41052A (fr)
MX (1) MX392749B (fr)
RU (1) RU2017115720A (fr)
TW (2) TW202300170A (fr)
WO (1) WO2016069234A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2678117C2 (ru) 2012-11-02 2019-01-23 Селджин Корпорейшн Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
EP3227675B1 (fr) 2014-12-03 2023-03-15 Celgene Corporation Antagonistes de l'activine-actrii et leurs utilisations pour le traitement du syndrome myelodysplasique
EP3298034A4 (fr) 2015-05-20 2019-02-13 Celgene Corporation Procédés de culture de cellules in vitro pour la beta-thalassemie a l'aide de pieges a ligands du recepteur de l'activine de type ii
WO2018067740A1 (fr) * 2016-10-05 2018-04-12 Acceleron Pharma, Inc. Compositions et méthode pour le traitement de la rénopathie
CA3043184A1 (fr) 2016-11-10 2018-05-17 Keros Therapeutics, Inc. Variants de type iia du recepteur de l'activine et leurs methodes d'utilisation
US11161887B2 (en) 2017-02-28 2021-11-02 Charité Universitätsmedizin Berlin Uromodulin for use in prevention and therapy of pathological crystallization
KR102628323B1 (ko) * 2017-03-24 2024-01-22 노바르티스 아게 심장질환 예방 및 치료 방법
IL320014A (en) 2018-01-12 2025-06-01 Keros Therapeutics Inc Activin receptor type iib variants and methods of use thereof
EP3771844B1 (fr) * 2018-03-30 2025-03-19 Hitachi Astemo, Ltd. Dispositif de frein de stationnement électrique
IL278546B2 (en) * 2018-05-09 2026-03-01 Keros Therapeutics Inc Activin receptor type IIA variants and methods of using them
KR20220054608A (ko) 2019-09-03 2022-05-03 노파르티스 아게 ActRII 수용체 길항제를 포함하는 간 질환 또는 장애 치료제
EP4121088A4 (fr) 2020-03-20 2024-07-03 Keros Therapeutics, Inc. Procédés d'utilisation de variants de récepteur de l'activine de type iib
EP4121078A4 (fr) 2020-03-20 2024-08-14 Keros Therapeutics, Inc. Chimères de type ii du récepteur d'activine et leurs méthodes d'utilisation
CN111474369A (zh) * 2020-04-22 2020-07-31 河北医科大学 一种平滑肌蛋白SM22α作为检测心血管疾病标志物的应用
US20230174620A1 (en) 2020-04-28 2023-06-08 Acceleron Pharma Inc. Actrii proteins and use in treating post-capillary pulmonary hypertension
KR20230026435A (ko) * 2020-06-23 2023-02-24 악셀레론 파마 인코포레이티드 Actrii 단백질 및 이의 용도
CN111870685B (zh) * 2020-07-16 2022-11-29 上海市同仁医院 运动相关多肽在制备防治缺血性心脏病药物中的应用
EP4674480A3 (fr) * 2020-10-02 2026-04-08 Keros Therapeutics, Inc. Procédés d'utilisation de variants du récepteur de l'activine de type ii
US12186370B1 (en) 2020-11-05 2025-01-07 Celgene Corporation ACTRIIB ligand trap compositions and uses thereof
CR20250375A (es) * 2023-03-09 2025-10-07 Merck Sharp & Dohme Llc Formulaciones que comprenden variantes de la proteína actriia
AU2024231427A1 (en) * 2023-03-09 2025-09-04 Merck Sharp & Dohme Llc Formulations comprising actriia polypeptide variants
WO2024238920A1 (fr) * 2023-05-18 2024-11-21 Keros Therapeutics, Inc. Méthodes d'utilisation de variants du récepteur de l'activine de type ii
CN121344183B (zh) * 2025-12-18 2026-03-27 成都医学院 检测ACVR2b的试剂在制备慢性肾脏病血管钙化诊断试剂盒中的用途

Family Cites Families (193)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0637520B2 (ja) 1985-07-03 1994-05-18 味の素株式会社 ポリペプチド
US4973577A (en) 1986-04-04 1990-11-27 The Salk Institute For Biological Studies FSH-releasing peptides
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
EP0548276A4 (en) 1990-09-13 1993-12-29 Children's Hospital Medical Center Of Northern California Method for increasing red blood cell production by treatment with activin or activin-related peptides
US5118667A (en) 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
US20050186593A1 (en) 1991-05-10 2005-08-25 The Salk Institute For Biological Studies Cloning and recombinant production of CRF receptor(s)
US5885794A (en) 1991-05-10 1999-03-23 The Salk Institute For Biological Studies Recombinant production of vertebrate activin receptor polypeptides and identification of receptor DNAs in the activin/TGF-β superfamily
AU654724B2 (en) 1991-05-10 1994-11-17 Salk Institute For Biological Studies, The Cloning and recombinant production of receptor(s) of the activin/TGF-beta superfamily
US6162896A (en) 1991-05-10 2000-12-19 The Salk Institute For Biological Studies Recombinant vertebrate activin receptors
CA2108770C (fr) 1991-06-25 2007-04-03 John M. Wozney Compositions de bmp-9
US6287816B1 (en) 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
US6692925B1 (en) 1992-11-17 2004-02-17 Ludwig Institute For Cancer Research Proteins having serine/threonine kinase domains, corresponding nucleic acid molecules, and their use
CA2153652A1 (fr) 1993-01-12 1994-07-21 The Johns Hopkins University School Of Medicine Facteur 3 de differenciation de croissance
ATE265529T1 (de) 1993-05-12 2004-05-15 Inst Genetics Llc Bmp-10 zusammensetzungen
US5637480A (en) 1993-05-12 1997-06-10 Genetics Institute, Inc. DNA molecules encoding bone morphogenetic protein-10
US5677196A (en) 1993-05-18 1997-10-14 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5831050A (en) 1993-06-07 1998-11-03 Creative Biomolecules, Inc. Morphogen cell surface receptor
DE69434934D1 (de) 1993-10-14 2007-04-12 Harvard College Verfahren zur induzierung und zur erhaltung neuronalen zellen
US5525490A (en) 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
US5658876A (en) 1994-04-28 1997-08-19 The General Hospital Corporation Activin antagonists as novel contraceptives
US5760010A (en) 1995-01-01 1998-06-02 Klein; Ira Method of treating liver disorders with a macrolide antibiotic
US5814565A (en) 1995-02-23 1998-09-29 University Of Utah Research Foundation Integrated optic waveguide immunosensor
EP0830459B1 (fr) 1995-04-11 2007-01-24 The General Hospital Corporation Systemes d'hybrides doubles inverses
US6132988A (en) 1995-10-27 2000-10-17 Takeda Chemical Industries, Ltd. DNA encoding a neuronal cell-specific receptor protein
GB9526131D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Recombinant chimeric receptors
US6004780A (en) 1996-03-26 1999-12-21 Human Genome Sciences, Inc. Growth factor HTTER36
US20050244867A1 (en) 1996-03-26 2005-11-03 Human Genome Sciences, Inc. Growth factor HTTER36
CA2268001A1 (fr) 1996-10-25 1998-05-07 G.D. Searle & Co. Agonistes de recepteurs d'erythropoietine permutes de maniere circulaire
US6605699B1 (en) 1997-01-21 2003-08-12 Human Genome Sciences, Inc. Galectin-11 polypeptides
US6231880B1 (en) 1997-05-30 2001-05-15 Susan P. Perrine Compositions and administration of compositions for the treatment of blood disorders
US6696260B1 (en) 1997-08-01 2004-02-24 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (GDF) binding proteins
WO1999006559A1 (fr) 1997-08-01 1999-02-11 The Johns Hopkins University School Of Medicine Procedes d'identification des recepteurs des facteurs de differenciation de la croissance
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
US6891082B2 (en) 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
AU8921698A (en) 1997-08-29 1999-03-16 Human Genome Sciences, Inc. Follistatin-3
US6953662B2 (en) 1997-08-29 2005-10-11 Human Genome Sciences, Inc. Follistatin-3
US6696411B1 (en) 1998-04-22 2004-02-24 Cornell Research Foundation, Inc. Canine erythropoietin gene and recombinant protein
WO2000015224A1 (fr) 1998-09-17 2000-03-23 Eli Lilly And Company Preparation a base de proteines
JP2002526073A (ja) 1998-09-22 2002-08-20 龍 余 新規のヒト生長分化因子のコード配列、そのｄｎａ配列によりコードされるポリペプチド、およびこれらの製造方法。
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US6548634B1 (en) 1998-09-30 2003-04-15 Chiron Corporation Synthetic peptides having FGF receptor affinity
US6777205B1 (en) 1998-11-06 2004-08-17 Sterrenbeld Biotechnologie North America, Inc. Host cells expressing recombinant human erythropoietin
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
JP2003517580A (ja) 1999-01-21 2003-05-27 メタモーフイクス・インコーポレーテツド 増殖分化因子インヒビター及びそれらの用途
CA2365449A1 (fr) 1999-04-19 2000-10-26 Kyowa Hakko Kogyo Co., Ltd. Inhibiteur de croissance de la tumeur androgeno-independante
US6468543B1 (en) 1999-05-03 2002-10-22 Zymogenetics, Inc. Methods for promoting growth of bone using ZVEGF4
ES2296634T3 (es) 1999-07-04 2008-05-01 Cardiovascular Research Institute Of Maastricht (Carim) Ensayo de diagnostico para proteina gla de matriz humana y su utilizacion como biomarcador.
JP2003513681A (ja) 1999-11-12 2003-04-15 マキシゲン・ホールディングス・リミテッド インターフェロンガンマ・コンジュゲート
IL150198A0 (en) 1999-12-15 2002-12-01 Res Dev Foundation Betaglycan as an inhibin receptor and uses thereof
JP4487376B2 (ja) 2000-03-31 2010-06-23 味の素株式会社 腎疾患治療剤
US6627424B1 (en) 2000-05-26 2003-09-30 Mj Bioworks, Inc. Nucleic acid modifying enzymes
EP1303605A2 (fr) 2000-07-19 2003-04-23 Eli Lilly And Company Acides nucleiques, vecteurs, cellules hotes, polypeptides et leurs utilisations
US6632180B1 (en) 2000-09-07 2003-10-14 John H. Laragh Method for evaluating and treating hypertension
DE10045591A1 (de) 2000-09-15 2002-04-04 Klaus Pfizenmaier Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine)
CA2418835A1 (fr) 2000-10-16 2002-04-25 Phylos, Inc. Echafaudages proteiniques internes pour analogues d'anticorps et autres proteines de liaison
US7087224B2 (en) 2000-10-31 2006-08-08 Amgen Inc. Method of treating anemia by administering IL-1ra
CN1474831A (zh) 2000-11-20 2004-02-11 ����ŵ˹������ѧ�йܻ� 膜支架蛋白
US20030082233A1 (en) 2000-12-01 2003-05-01 Lyons Karen M. Method and composition for modulating bone growth
EP1370287A2 (fr) 2000-12-01 2003-12-17 Wyeth Methode et composition permettant de moduler la croissance osseuse
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
TWI329129B (en) 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
US20040132675A1 (en) 2002-02-08 2004-07-08 Calvin Kuo Method for treating cancer and increasing hematocrit levels
US7294472B2 (en) 2001-03-14 2007-11-13 Caden Biosciences Method for identifying modulators of G protein coupled receptor signaling
US20040121008A1 (en) 2001-03-16 2004-06-24 Keiko Shiraishi Process for producing sustained release preparation
JP4369662B2 (ja) 2001-04-26 2009-11-25 アビディア インコーポレイテッド 単量体ドメインのコンビナトリアルライブラリー
PL403488A1 (pl) 2001-05-24 2013-07-08 Zymogenetics, Inc. Zastosowanie bialka fuzyjnego TACI-immunoglobulina, bialko fuzyjne, czasteczka kwasu nukleinowego kodujaca bialko fuzyjne, kompozycja farmaceutyczna i sposób wytwarzania bialka fuzyjnego TACI-immunoglobulina
WO2002094864A2 (fr) 2001-05-25 2002-11-28 Genset S.A. Adnc et proteines humaines, ainsi que leurs utilisations
AUPR638101A0 (en) 2001-07-13 2001-08-09 Bioa Pty Limited Composition and method for treatment of disease
US6855344B2 (en) 2001-07-17 2005-02-15 Integrated Chinese Medicine Holdings, Ltd. Compositions and methods for prostate and kidney health and disorders, an herbal preparation
KR100912852B1 (ko) 2001-07-17 2009-08-18 데이진 가부시키가이샤 ＰＰＡＲ δ활성화 작용을 측정하는 것을 특징으로 하는물질의 선택방법 및 약제
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
US6784154B2 (en) 2001-11-01 2004-08-31 University Of Utah Research Foundation Method of use of erythropoietin to treat ischemic acute renal failure
US20030144203A1 (en) 2001-12-19 2003-07-31 Voyager Pharmaceutical Corporation Methods for slowing senescence and treating and preventing diseases associated with senescence
US6998118B2 (en) 2001-12-21 2006-02-14 The Salk Institute For Biological Studies Targeted retrograde gene delivery for neuronal protection
MXPA04007583A (es) 2002-02-11 2005-04-25 Genentech Inc Variantes de anticuerpo con tasas mas rapidas de asociacion a antigeno.
BR0307907A2 (pt) 2002-02-21 2011-07-05 Wyeth Corp gasp1: proteìna contendo domìnio de folistatina
US20030219846A1 (en) 2002-02-28 2003-11-27 Pfizer Inc. Assay for activity of the ActRIIB kinase
AU2003232485A1 (en) 2002-04-18 2003-10-27 Mtm Laboratories Ag Neopeptides and methods useful for detection and treatment of cancer
AU2003261246A1 (en) 2002-08-16 2004-03-03 Wyeth Bmp-2 estrogen responsive element and methods of using the same
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
US20040223966A1 (en) 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
AU2002953327A0 (en) 2002-12-12 2003-01-09 Monash University Methods of diagnosing prognosing and treating activin associated diseases and conditions
BRPI0407276A (pt) 2003-02-07 2006-01-31 Prometic Biosciences Inc ácidos graxos, glicerìdeos e análogos com comprimento de cadeia médio, como estimulantes de eritropoiese
US20040197828A1 (en) 2003-03-26 2004-10-07 Gaddy Dana P. Method for diagnosis and treatment of bone turnover
WO2005028517A2 (fr) 2003-05-09 2005-03-31 The General Hospital Corporation PROTEINES DE FUSION SOLUBLES DU RECEPTEUR TGF- ss DE TYPE III
WO2004108157A2 (fr) 2003-06-02 2004-12-16 Wyeth Methodes de traitement et de prevention des troubles neuromusculaires
CN1835974A (zh) 2003-06-16 2006-09-20 细胞技术研究与发展公司 对硬化素特异的抗体和用于增加骨矿化的方法
US7611465B2 (en) 2003-07-15 2009-11-03 Board Of Regents, The University Of Texas System Rapid and accurate detection of bone quality using ultrasound critical angle reflectometry
WO2005009460A2 (fr) 2003-07-25 2005-02-03 Medexis, S.A. Composition pharmaceutique comportant l'activine a, l'alk-4 ou leurs derives pour le traitement des troubles ophtalmiques ou du cancer
DE10335211A1 (de) 2003-08-01 2005-02-17 Robert Bosch Gmbh Kraftstoff-Einspritzvorrichtung für eine Brennkraftmaschine
WO2005025601A1 (fr) 2003-09-15 2005-03-24 Monash University Isoformes de follistatine et leurs utilisations
US8895540B2 (en) 2003-11-26 2014-11-25 DePuy Synthes Products, LLC Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
CA2553883C (fr) 2004-01-22 2013-04-02 Merck Patent Gesellschaft Mit Beschraenkter Haftung Anticorps anticancereux a fixation complementaire reduite
US20050197292A1 (en) 2004-01-30 2005-09-08 Glennda Smithson Compositions and methods for treating T-cell mediated pathological conditions
JP2007530055A (ja) 2004-03-26 2007-11-01 アクセルロン ファーマ インコーポレーテッド Ｂｍｐ−３プロペプチドおよび関連する方法
CA2561809A1 (fr) 2004-03-31 2005-10-20 Xencor, Inc. Variants de bmp-7 ayant des proprietes ameliorees
WO2005113590A2 (fr) 2004-05-12 2005-12-01 Acceleron Pharma Inc. Propeptides de bmp10 et procédés correspondants
EP1771557B1 (fr) 2004-06-24 2014-12-31 Acceleron Pharma Inc. Propeptides GDF3 et méthodes associées
JP2008507288A (ja) 2004-07-23 2008-03-13 アクセルロン ファーマ インコーポレーテッド ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物
MX2007000976A (es) 2004-08-12 2007-04-10 Wyeth Corp Tratamiento combinado para diabetes, obesidad y enfermedades cardiovasculares utilizando inhibidores del factor 8 de crecimiento y diferenciacion.
EP1804824B1 (fr) 2004-09-29 2017-01-04 Icahn School of Medicine at Mount Sinai Compositions modulant la fsh et le recepteur de la fsh et methodes inhibant la resorption osseuse osteoclastique et les pertes osseuses de l'osteoporose
CA2587424A1 (fr) 2004-11-16 2006-05-26 Avidia Research Institute Squelettes proteiques et leurs utilisations
NZ538097A (en) 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
EP2954903A1 (fr) 2005-02-16 2015-12-16 The General Hospital Corporation Utilisations d'antagonistes de bmp réguler le métabolisme du fer
JPWO2006115274A1 (ja) 2005-04-26 2008-12-18 味の素株式会社 骨髄赤血球前駆細胞分化促進剤
JP2007099764A (ja) 2005-09-09 2007-04-19 Ajinomoto Co Inc 血糖低下剤
BRPI0616589A2 (pt) 2005-09-28 2011-06-28 Zymogenetics Inc polipeptìdeo, e, métodos para produzir um anticorpo para um polipeptìdeo, para reduzir ou inibir a inflamação e para tratar um mamìfero afligido com uma doença inflamatória
US20070248597A1 (en) * 2005-10-21 2007-10-25 Henley Charles M Iii Methods of decreasing vascular calcification using IL-1 inhibitors
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
BRPI0618947B1 (pt) 2005-11-23 2022-07-19 Acceleron Pharma Inc Polipeptídeo actriia que se liga à ativina, polinucleotídeo isolado, polinucleotídeo recombinante, métodopara preparar um polipeptídeo actriia que se liga à ativina, preparação farmacêutica e uso de uma proteína de fusão actriia-fc para promover o crescimento ósseo e inibir a ressorção óssea
US20070149458A1 (en) 2005-12-06 2007-06-28 Amgen Inc. Uses of myostatin antagonists
WO2007071023A1 (fr) 2005-12-20 2007-06-28 Merck Frosst Canada Ltd. Composés hétéroaromatiques en tant qu'inhibiteurs de stéaroyl-coenzyme a delta-9 désaturase
CA2634940A1 (fr) 2005-12-21 2007-07-05 Schering Corporation Traitement de la steatose hepatique non alcoolique au moyen d'agents hypocholesterolemiants et/ou dun agoniste inverse/antagoniste du recepteur h3
WO2007076127A2 (fr) 2005-12-22 2007-07-05 Biogen Idec Ma Inc Modulateurs du facteur de croissance transformant
JP4925364B2 (ja) 2006-01-20 2012-04-25 ベックマン コールター， インコーポレイテッド 鉄欠乏を検出する方法
US7820721B2 (en) 2006-01-25 2010-10-26 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
KR20080098615A (ko) 2006-02-28 2008-11-11 웰스태트 테러퓨틱스 코포레이션 물질대사 장애의 치료용 화합물
US8008074B2 (en) 2006-03-20 2011-08-30 The Uab Research Foundation Compositions and methods for improving bone mass through modulation of receptors of PTH and fragments thereof
CA2650131A1 (fr) 2006-04-14 2007-10-25 Amgen Inc. Anticorps diriges contre un agoniste du recepteur de l'erythropoietine
AU2007249827A1 (en) 2006-05-09 2007-11-22 Colorado State University Research Foundation Methods for treating blood disorders
MX2009000722A (es) 2006-07-21 2009-06-11 Lyne Lab Composiciones liquidas de acetato de calcio.
GB0615129D0 (en) 2006-07-29 2006-09-06 Univ Cardiff Anti-cancer activity of BMP-9 and BMP-10 and their use in cancer therapies
WO2008030367A2 (fr) 2006-09-01 2008-03-13 The General Hospital Corporation Inhibiteurs sélectifs de la myostatine
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
WO2008060139A1 (fr) 2006-11-17 2008-05-22 Erasmus University Medical Center Rotterdam Procédés destinés à contrôler la minéralisation d'une matrice extracellulaire, procédés thérapeutiques se fondant sur ces procédés et médicaments destinés à être utilisés dans le cadre de ces procédés
WO2008073292A2 (fr) 2006-12-08 2008-06-19 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Procédé destiné à protéger les cellules épithéliales tubulaires rénales de rcn
CA2672581A1 (fr) 2006-12-14 2008-06-19 Forerunner Pharma Research Co., Ltd. Anticorps monoclonal anti-claudine 3, et traitement et diagnostic du cancer au moyen d'un tel anticorps
US8895016B2 (en) * 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
CA2672758C (fr) 2006-12-18 2019-07-30 Acceleron Pharma Inc. Antagonistes de l'activine-actrii et ses utilisations pour accroitre les niveaux de globules rouges
US20100028332A1 (en) 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
TWI584815B (zh) 2007-02-01 2017-06-01 艾瑟勒朗法瑪公司 活化素-ＡｃｔＲＩＩａ拮抗劑及其治療或預防乳癌之用途
TW201627320A (zh) 2007-02-02 2016-08-01 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
MX2009008510A (es) 2007-02-09 2010-01-15 Acceleron Pharma Inc Antagonistas de activina-actriia y usos para promover el crecimiento de huesos en pacientes con cancer.
TW201718635A (zh) 2007-03-06 2017-06-01 安美基公司 變異之活動素受體多肽及其用途
EP2150560A1 (fr) 2007-06-01 2010-02-10 Wyeth Méthodes et compositions destinées à moduler l'activité de bmp-10
WO2009009059A1 (fr) 2007-07-09 2009-01-15 Biogen Idec Ma Inc. Composés spiro en tant qu'antagonistes du tgf-bêta
AU2008285289A1 (en) 2007-08-03 2009-02-12 Biomarin Iga Limited Drug combinations for the treatment of Duchenne muscular dystrophy
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
GB0715938D0 (en) 2007-08-15 2007-09-26 Vastox Plc Method of treatment of duchenne muscular dystrophy
WO2009025651A1 (fr) 2007-08-17 2009-02-26 University Of Maine System Board Of Trustees Peptide biologiquement actif et procédé d'utilisation correspondant
CA2699936A1 (fr) 2007-09-18 2009-03-26 Acceleron Pharma Inc. Antagonistes de l'activine-actriia et utilisations pour reduire ou empecher la secretion de fsh
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
CN101925611A (zh) 2007-11-21 2010-12-22 安姆根有限公司 Wise结合剂和表位
EP2265603B1 (fr) 2008-03-13 2014-05-07 The General Hospital Corporation Inhibiteurs de la voie de signalisation bmp
WO2009137075A1 (fr) 2008-05-06 2009-11-12 Acceleron Pharma Inc. Anticorps anti-activine et leurs utilisations pour promouvoir la croissance osseuse
WO2009137613A2 (fr) 2008-05-06 2009-11-12 Joslin Diabetes Center, Inc. Procédés et compositions pour induire une adipogenèse brune
KR20110031951A (ko) 2008-06-26 2011-03-29 악셀레론 파마 인코포레이티드 액티빈-ａｃｔｒｉｉａ의 길항물질 및 적혈구 수준을 증가시키기 위한 이들의 용도
EP2315602A4 (fr) 2008-06-26 2011-11-02 Acceleron Pharma Inc Procédés pour administrer un antagoniste d' actriib et surveiller des patients traités
US8637611B2 (en) 2008-08-13 2014-01-28 Designer Molecules, Inc. Amide-extended crosslinking compounds and methods for use thereof
DK3750552T5 (da) 2008-08-14 2024-08-26 Acceleron Pharma Inc Gdf-fælder
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
PE20150680A1 (es) * 2008-11-26 2015-05-16 Amgen Inc Variantes de polipeptidos receptores de activina iib y aplicaciones de estos
AU2010204985A1 (en) 2009-01-13 2011-08-04 Acceleron Pharma Inc. Methods for increasing adiponectin
BRPI1008815A2 (pt) 2009-02-05 2018-02-14 Digna Biotech, S.L composições farmacêuticas compreendendo peptídeos inibidores de tgf-beta1
ES2655877T3 (es) 2009-04-27 2018-02-22 Novartis Ag Composiciones y métodos para aumentar el crecimiento muscular
MX355042B (es) 2009-06-08 2018-04-02 Acceleon Pharma Inc Metodos para aumentar adipositos termogenicos.
CN107267520A (zh) 2009-06-12 2017-10-20 阿塞勒隆制药公司 截短的actriib‑fc融合蛋白
KR102170682B1 (ko) 2009-08-13 2020-10-28 악셀레론 파마 인코포레이티드 적혈구 수준을 증가시키기 위한 ｇｄｆ 트랩과 에리트로포이에틴 수용체 활성인자의 병용
EP3202459B1 (fr) 2009-09-09 2021-04-14 Acceleron Pharma Inc. Antagonistes d'actriib et dosage et utilisations de ceux-ci pour traiter l'obésité ou le diabète en régulant le taux de graisse corporelle
EP3260130B1 (fr) 2009-11-03 2021-03-10 Acceleron Pharma Inc. Procédés de traitement de la maladie du foie gras
ES2658292T3 (es) 2009-11-17 2018-03-09 Acceleron Pharma, Inc. Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular
RU2421126C1 (ru) 2010-01-25 2011-06-20 ФГУ ВПО Кубанский государственный медицинский университет Росздрава (КГМУ) Способ прогнозирования эффективности планируемой стандартной терапии острого нефрита
WO2012027065A2 (fr) 2010-08-27 2012-03-01 Celgene Corporation Polythérapie pour traiter des maladies
DK3520805T3 (da) 2011-10-17 2021-04-19 Acceleron Pharma Inc Sammensætninger til behandling af myelofibrose
CA2874117C (fr) 2012-07-02 2021-10-12 Kyowa Hakko Kirin Co., Ltd. Agent therapeutique a base d'anticorps anti-bmp9 en tant que principe actif, pour le traitement de l'anemie, notamment une anemie renale et une anemie liee a un cancer
JP6401172B2 (ja) 2012-10-24 2018-10-10 セルジーン コーポレイション 貧血の治療方法
CA2889209C (fr) 2012-10-24 2023-08-22 Celgene Corporation Biomarqueur utilisable dans le traitement de l'anemie
RU2678117C2 (ru) 2012-11-02 2019-01-23 Селджин Корпорейшн Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений
EP3131931B1 (fr) 2014-04-18 2020-10-21 Acceleron Pharma Inc. Procédés d'augmentation des taux de globules rouges et de traitement de la drépanocytose
CN114699529A (zh) 2014-06-13 2022-07-05 阿塞勒隆制药公司 用于治疗溃疡的方法和组合物
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
MA41119A (fr) 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
EP3227675B1 (fr) 2014-12-03 2023-03-15 Celgene Corporation Antagonistes de l'activine-actrii et leurs utilisations pour le traitement du syndrome myelodysplasique
KR101759725B1 (ko) * 2015-04-27 2017-08-01 동우당제약(주) 지골피추출물로부터 분리된 디하이드로파세익 애시드 쓰리프라임-오-베타-디-글루코피라노사이드를 포함하는 골다공증 예방 및 치료용 조성물
TWI814187B (zh) 2015-05-13 2023-09-01 美商西建公司 使用ACTRII配位體捕捉以治療β-地中海型貧血
EP3298034A4 (fr) 2015-05-20 2019-02-13 Celgene Corporation Procédés de culture de cellules in vitro pour la beta-thalassemie a l'aide de pieges a ligands du recepteur de l'activine de type ii
EP3370754B1 (fr) 2015-11-04 2026-04-29 Acceleron Pharma, Inc. Méthodes pour augmenter les taux d'érythrocytes et traiter l'érythropoïèse inefficace
JP7072507B2 (ja) 2015-11-23 2022-05-20 アクセルロン ファーマ インコーポレイテッド 眼の障害を処置するための方法
MX2018004511A (es) 2016-05-27 2018-08-01 Novelis Inc Aleacion de alta fuerza y resistente a la corrosion para uso en sistemas hvac&r.
AU2017296040C1 (en) 2016-07-15 2023-06-22 Acceleron Pharma Inc. Compositions and methods for treating pulmonary hypertension
LT3490582T (lt) 2016-07-27 2024-07-25 Acceleron Pharma Inc. Kompozicijos, skirtos naudoti gydant mielofibrozę
AU2017338916B2 (en) 2016-10-05 2022-03-24 Acceleron Pharma Inc. Variant ActRIIB proteins and uses thereof
WO2018231905A1 (fr) 2017-06-14 2018-12-20 Celgene Corporation Méthodes de traitement de la myélofibrose associée à un néoplasme myéloprolifératif et de l'anémie
JP7663502B2 (ja) 2018-10-31 2025-04-16 セルジーン コーポレイション 環状鉄芽球が見られる対象における非常に低リスク、低リスクまたは中程度のリスクの骨髄異形成症候群による貧血の、アクチビン－ａｃｔｒｉｉリガンドトラップを用いた治療
US20230181690A1 (en) 2020-04-13 2023-06-15 Celgene Corporation Methods for treating anemia using an actriib ligand trap and fedratinib
CA3177632A1 (fr) 2020-05-15 2021-11-18 Melih ACAR Methodes et compositions pour traiter l'anemie a l'aide de pieges a ligands actriib et d'inhibiteurs de mtor

Also Published As

Publication number Publication date
EP3204118B8 (fr) 2024-04-10
CA2964129A1 (fr) 2016-05-06
TW201625288A (zh) 2016-07-16
AU2015339786A1 (en) 2017-05-25
CN107206255A (zh) 2017-09-26
JP2021169464A (ja) 2021-10-28
AU2021203571A1 (en) 2021-07-01
MX2017004675A (es) 2018-06-12
EP3204118A4 (fr) 2018-10-03
WO2016069234A1 (fr) 2016-05-06
MX392749B (es) 2025-03-24
RU2017115720A (ru) 2018-11-15
US11813308B2 (en) 2023-11-14
RU2017115720A3 (fr) 2019-05-08
TW202300170A (zh) 2023-01-01
EP3204118B1 (fr) 2024-03-06
HK1244741A1 (zh) 2018-08-17
ES2978963T3 (es) 2024-09-23
IL251649B (en) 2022-02-01
AU2015339786B2 (en) 2021-03-04
US20170304397A1 (en) 2017-10-26
JP2017533191A (ja) 2017-11-09
IL251649A0 (en) 2017-06-29
EP3204118A1 (fr) 2017-08-16
KR20170088836A (ko) 2017-08-02

Similar Documents

Publication Publication Date Title
FR25C1001I2 (fr) Compositions d'anticorps pour le traitement de tumeurs
MA49144A (fr) Polythérapies pour le traitement du cancer
IL251649B (en) Treatment of cardiovascular disease using actrii ligand traps
EP3534907A4 (fr) Compositions et méthodes de traitement d'une maladie hépatique
EP3494142A4 (fr) Anticorps anti-siglec-7 pour le traitement du cancer
EP3291815A4 (fr) Méthodes de traitement d'une maladie neurodégénérative
MA43746A (fr) Dérivés de 2-cyanoisoindoline pour le traitement du cancer
EP3233878A4 (fr) Phosphoramidates pour le traitement du virus de l'hépatite b
HUE053239T2 (hu) Humanizált tau-ellenanyagok Alzheimer-kór kezelésére
MA50409A (fr) Polythérapies pour le traitement du cancer
MA48637A (fr) Polythérapies pour le traitement du cancer
IL247111A0 (en) Preventive or therapeutic agent for kidney disease
MA44864A (fr) Trithérapie pour le traitement d'une maladie intestinale inflammatoire
MA41449A (fr) Polythérapies pour le traitement de cancers
EP3389645A4 (fr) Combinaisons pour le traitement du cancer
EP3359255A4 (fr) Polythérapies pour le traitement du cancer
EP3393468A4 (fr) Méthodes pour le traitement d'une maladie immunodéficiente
EP3432892A4 (fr) Antagonistes dérivés du mannose de fimh utiles pour le traitement d'une maladie
EP3386522A4 (fr) Compositions et méthodes pour le traitement du cancer du sein métastatique her2-positif
EP3490561A4 (fr) Combinaisons pour le traitement du cancer
EP3331510A4 (fr) Thérapies combinatoires pour le traitement du cancer
EP3383497A4 (fr) Nouveaux anticorps pour le traitement de cancers
EP3345002A4 (fr) Sélection de patients pour une polythérapie
EP3503887A4 (fr) Combinaisons pour le traitement du cancer
EP4223359C0 (fr) Dispositif non invasif de traitement du reflux gastro- sophagien pathologique